NR 100 mg is a studied amount of nicotinamide riboside, a precursor used in NAD metabolism. The most useful evidence detail is easy to miss: a rise from a group’s own baseline is not the same as a significant difference from placebo.
That distinction matters when a lower-dose product cites a broad statement that NR increases NAD. It also matters when 100 mg NR is only one ingredient in a formula containing other NAD-related compounds.
The 100 mg NR trial result needs its comparator: an increase from baseline did not establish a significant difference from placebo. A blend containing 100 mg NR is a separate product.
Read the 100 mg result beyond the abstract
In the 2019 eight-week NR trial, the 100 mg group showed a significant blood-NAD increase from its own baseline at day 14, but its levels were similar to placebo at all measured time points. The full results are more informative than a general claim about all studied amounts.
This does not prove that 100 mg can never have an effect. It limits what that particular trial establishes about the comparison.
Why baseline and placebo answer different questions
A baseline comparison asks whether a group changed over time. A placebo comparison asks whether its change differs from what occurred in a comparison group under the study conditions. Biological variation, measurement variation, and other influences can make the answers different.
An advertisement should state which comparison produced its percentage or significance claim. A larger-looking number without that context can overstate the evidence.
A real blend can contain 100 mg NR
Renue’s NAD+ Complete label lists 100 mg NR per two-capsule serving alongside NMN, trigonelline, and direct NAD+. That product is not the isolated 100 mg NR intervention from the trial.
The Renue review separates the ingredients. Adding their masses does not produce a meaningful total amount of NR, and a result from one ingredient does not establish the effect of the finished blend.
Do not label it an established beginner dose
A low-looking amount can be marketed as gentle or introductory without a trial establishing that it is the right starting point for every person. Suitability still depends on the actual product, medical history, and other substances used.
If a supplement is being considered for persistent fatigue or another health concern, the label number does not identify the cause. A discussion with a clinician can clarify the question before a purchase becomes a self-directed dose experiment.
The next comparison should stay specific
Compare NR 300 mg for a different studied amount and NR 500 mg for the distinction between a capsule amount and a daily study total. These are evidence and label guides, not a recommendation to increase use.
When shopping, record NR per full serving and every other active ingredient. That makes it possible to distinguish a plain NR product from a multi-pathway marketing claim.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Conze et al. (2019): NR dose-ranging trial Eight-week trial of 100, 300, and 1,000 mg NR. The 100 mg blood-NAD result differed from baseline but not placebo; biomarker findings are not longevity outcomes.
- Renue By Science: NAD+ Complete Current multi-ingredient label differs from some older listings; on-page starting prices vary.
- FDA: questions and answers on dietary supplements Regulatory categories and limits of premarket review.
- FDA: mixing medications and dietary supplements General interaction and surgery guidance; specific risks must be matched to the actual ingredient and medication.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.